Antibody and antibody fragment introduced new modification sites
First Claim
1. A monoclonal IgG antibody or antigen-binding fragment thereof, wherein said monoclonal IgG antibody or antigen-binding fragment thereof comprises a human constant region in which one or more amino acids having a solvent accessible surface area ratio of 20% or less are substituted with a cysteine residue, wherein said one or more amino acids that are substituted are selected from the group consisting of (1) to (5):
- (1) the amino acid at position 124 of human IgG light chain region in Kabat numbering,(2) the amino acid at position 198 of human IgG light chain region in Kabat numbering,(3) the amino acid at position 201 of human IgG light chain region in Kabat numbering,(4) the amino acid at position 147 of human IgG heavy chain region in EU numbering, and(5) the amino acid at position 183 of human IgG heavy chain region in EU numbering.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to an antibody or antibody fragment comprising novel Cys residue, to which a hydrophilic macromolecular group or amphipathic macromolecular group can be bound at a high efficiency. In addition, the present invention relates to a monoclonal antibody modified product or an antibody fragment modified product in which cysteine residue is chemically modified.
15 Citations
14 Claims
-
1. A monoclonal IgG antibody or antigen-binding fragment thereof, wherein said monoclonal IgG antibody or antigen-binding fragment thereof comprises a human constant region in which one or more amino acids having a solvent accessible surface area ratio of 20% or less are substituted with a cysteine residue, wherein said one or more amino acids that are substituted are selected from the group consisting of (1) to (5):
-
(1) the amino acid at position 124 of human IgG light chain region in Kabat numbering, (2) the amino acid at position 198 of human IgG light chain region in Kabat numbering, (3) the amino acid at position 201 of human IgG light chain region in Kabat numbering, (4) the amino acid at position 147 of human IgG heavy chain region in EU numbering, and (5) the amino acid at position 183 of human IgG heavy chain region in EU numbering. - View Dependent Claims (3, 4, 5, 10, 11, 12, 13, 14)
-
- 2. A monoclonal IgG antibody or antigen-binding fragment thereof, wherein said monoclonal IgG antibody or antigen-binding fragment thereof comprises a human constant region in which an amino acid having a solvent accessible surface area ratio of 20% or less is substituted with a cysteine residue, wherein said amino acid having a solvent accessible surface area ratio of 20% or less is position 140 of human IgG heavy chain region in EU numbering, and wherein said substituted cysteine residue is chemically modified.
Specification